Perceptive Advisors - Q1 2014 holdings

Add to watchlist

$952 Million is the total value of Perceptive Advisors's 127 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 93.6% .

All

			Value		Shares		↓ Weighting
ACRX		ACELRX PHARMACEUTICALS INC	$78,954,000	+6.2%	6,574,060	0.0%	8.30%	-7.1%
NBIX	Buy	NEUROCRINE BIOSCIENCES INC	$74,372,000	+90.3%	4,619,367	+10.4%	7.82%	+66.5%
SRPT	Sell	SAREPTA THERAPEUTICS INC	$69,182,000	-2.5%	2,878,979	-17.4%	7.27%	-14.7%
VRTX	Sell	VERTEX PHARMACEUTICALS INC	$41,140,000	-31.8%	581,728	-28.3%	4.32%	-40.3%
TSRO	Sell	TESARO INC	$36,262,000	-11.2%	1,230,070	-15.0%	3.81%	-22.3%
CELG	Sell	CELGENE CORP	$28,786,000	-66.5%	206,200	-59.5%	3.02%	-70.7%
LBIO	New	LION BIOTECHNOLOGIES	$28,320,000	–	3,000,000	+100.0%	2.98%	–
EXAS	Sell	EXACT SCIENCES CORP	$25,862,000	+12.3%	1,825,150	-7.3%	2.72%	-1.7%
HRTX	New	HERON THERAPEUTICS INC	$24,515,000	–	1,762,426	+100.0%	2.58%	–
DYAX	Buy	DYAX CORP	$23,013,000	+31.0%	2,562,674	+9.9%	2.42%	+14.6%
RTRX	Sell	RETROPHIN INC	$22,138,000	+200.5%	1,044,292	-0.8%	2.33%	+162.8%
VRTX	New	VERTEX PHARMACEUTICALS INCput	$21,216,000	–	300,000	+100.0%	2.23%	–
WAG	Sell	WALGREEN CO	$20,101,000	+8.7%	304,419	-5.5%	2.11%	-4.9%
F113PS	Sell	COVIDIEN PLC	$19,365,000	-24.1%	262,900	-29.9%	2.04%	-33.6%
PTCT	New	PTC THERAPEUTICS	$17,558,000	–	671,736	+100.0%	1.84%	–
XNCR	Sell	XENCOR INC	$17,462,000	+21.8%	1,488,672	-5.1%	1.84%	+6.6%
NEPT	Buy	NEPTUNE TECHNOLOGIES BIORESO	$16,550,000	-3.3%	6,700,444	+13.6%	1.74%	-15.4%
ACAD	New	ACADIA PHARMACEUTICALS INC	$16,204,000	–	666,000	+100.0%	1.70%	–
VSAR	New	VERSARTIS INC	$15,063,000	–	501,266	+100.0%	1.58%	–
SGMO	New	SANGAMO BIOSCIENCES INC	$14,464,000	–	800,000	+100.0%	1.52%	–
PRTA	New	PROTHENA CORP PLC	$13,409,000	–	350,000	+100.0%	1.41%	–
ANAC	New	ANACOR PHARMACEUTICALS INC	$12,947,000	–	647,015	+100.0%	1.36%	–
EXAS	New	EXACT SCIENCES CORPput	$12,753,000	–	900,000	+100.0%	1.34%	–
MGNX	Sell	MACROGENICS INC	$12,494,000	-36.5%	448,945	-37.4%	1.31%	-44.5%
CLVS	Buy	CLOVIS ONCOLOGY INC	$11,929,000	+547.3%	172,217	+463.1%	1.25%	+467.0%
ZLTQ	Buy	ZELTIQ AESTHETICS INC	$11,503,000	+99.0%	586,013	+91.8%	1.21%	+74.2%
MYL	Sell	MYLAN INC	$11,353,000	-33.4%	232,500	-40.8%	1.19%	-41.7%
TARO	Buy	TARO PHARMACEUTICAL INDS LTD	$10,768,000	+92.4%	97,011	+71.4%	1.13%	+68.3%
FLML	New	FLAMEL TECHNOLOGIES SAsponsored adr	$10,720,000	–	800,000	+100.0%	1.13%	–
ECYT	Sell	ENDOCYTE INC	$10,357,000	+97.9%	435,000	-35.2%	1.09%	+73.0%
SPNC	Sell	SPECTRANETICS CORP	$10,080,000	+16.5%	332,554	-4.0%	1.06%	+1.8%
INCY	Sell	INCYTE CORP	$9,837,000	-27.7%	183,800	-31.6%	1.03%	-36.8%
OPHT	Buy	OPHTHOTECH CORP	$8,935,000	+268.3%	250,000	+233.3%	0.94%	+222.7%
ITMN	New	INTERMUNE INC	$8,702,000	–	260,000	+100.0%	0.91%	–
SRPT	New	Sarepta Therapeutics Inccall	$8,413,000	–	350,000	+100.0%	0.88%	–
HCA	New	HCA HOLDINGS INC	$7,875,000	–	150,000	+100.0%	0.83%	–
CHTP	Sell	CHELSEA THERAPEUTICS INTL LT	$7,185,000	-4.7%	1,301,639	-23.5%	0.76%	-16.6%
DSCI	New	DERMA SCIENCES INC	$6,756,000	–	532,800	+100.0%	0.71%	–
CYTK	New	CYTOKINETICS INCcall	$6,650,000	–	700,000	+100.0%	0.70%	–
INSM	New	INSMED INC	$6,474,000	–	340,000	+100.0%	0.68%	–
ALQA	Buy	ALLIQUA	$6,472,000	+60.2%	784,594	+40.7%	0.68%	+40.2%
TRVN	New	TREVENA INC	$6,052,000	–	770,000	+100.0%	0.64%	–
RLYP	Sell	RELYPSA INC	$5,402,000	-36.7%	181,200	-46.9%	0.57%	-44.6%
CSU	Sell	CAPITAL SR LIVING CORP	$5,263,000	+5.1%	202,500	-3.0%	0.55%	-8.0%
ARWR	New	ARROWHEAD RESH CORP	$5,210,000	–	317,300	+100.0%	0.55%	–
ENZY	New	ENZYMOTEC LTD	$4,717,000	–	214,219	+100.0%	0.50%	–
KERX	New	KERYX BIOPHARMACEUTICALS INC	$4,686,000	–	275,000	+100.0%	0.49%	–
ARNI		ARNO THERAPEUTICS	$4,517,000	-20.7%	2,034,721	0.0%	0.48%	-30.6%
GMED	New	GLOBUS MED INCcl a shrs	$4,520,000	–	170,000	+100.0%	0.48%	–
AERI	Sell	AERIE PHARMACEUTICALS INC	$4,482,000	-16.8%	211,518	-29.5%	0.47%	-27.2%
SHPG	Buy	SHIRE PLCsponsored adr	$4,456,000	+215.4%	30,000	+200.0%	0.47%	+175.3%
GILD		GILEAD SCIENCES INC	$3,543,000	-5.7%	50,000	0.0%	0.37%	-17.5%
ABBV	Sell	ABBVIE INC	$3,444,000	-81.4%	67,000	-80.9%	0.36%	-83.7%
ALNY	New	ALNYLAM PHARMACEUTICALS INC	$3,357,000	–	50,000	+100.0%	0.35%	–
ITMN	New	INTERMUNE INCcall	$3,347,000	–	100,000	+100.0%	0.35%	–
ACST	Sell	ACASTI PHARMA INCcl a shrs	$3,299,000	-37.0%	2,869,447	-34.6%	0.35%	-44.8%
CMRX	Sell	CHIMERIX INC	$3,199,000	+41.4%	140,000	-6.7%	0.34%	+23.5%
FPRX	Buy	FIVE PRIME THERAPEUTICS INC	$2,949,000	+32.5%	150,000	+13.2%	0.31%	+16.1%
BOTA	New	BIOTA PHARMACEUTIALS INC	$2,536,000	–	415,000	+100.0%	0.27%	–
VSTM		VERASTEM INC	$2,391,000	-5.0%	220,000	0.0%	0.25%	-16.9%
TNDM	Sell	TANDEM DIABETES CARE INC	$2,339,000	-27.7%	105,900	-15.7%	0.25%	-36.8%
MGCD	Buy	MGC DIAGNOSTICS CORP	$2,310,000	+1.6%	206,957	+15.2%	0.24%	-11.0%
ATHX	Sell	ATHERSYS INC	$2,273,000	-46.5%	701,582	-58.8%	0.24%	-53.2%
GNVC	New	GENVEC INC	$2,173,000	–	820,000	+100.0%	0.23%	–
TKMR	New	TEKMIRA PHARMACEUTICALS CORPput	$2,149,000	–	100,000	+100.0%	0.23%	–
MDVN	New	MEDIVATION INC	$2,053,000	–	31,900	+100.0%	0.22%	–
FOLD	New	AMICUS THERAPEUTICS INC	$2,000,000	–	966,300	+100.0%	0.21%	–
ATRC	New	ATRICURE INC	$1,881,000	–	100,000	+100.0%	0.20%	–
UPI	Buy	UROPLASTY INC	$1,880,000	+119.4%	517,791	+64.9%	0.20%	+92.2%
OXGN	New	OXIGENE INC	$1,865,000	–	500,000	+100.0%	0.20%	–
QCOR	New	QUESTCOR PHARMACEUTICALS	$1,857,000	–	28,600	+100.0%	0.20%	–
IDIX		IDENIX PHARMACEUTICALS INCcall	$1,809,000	+0.8%	300,000	0.0%	0.19%	-11.6%
CGEN	New	COMPUGEN LTDord	$1,787,000	–	170,000	+100.0%	0.19%	–
AQXP	New	AQUINOX PHARMACEUTICALS INC	$1,655,000	–	130,000	+100.0%	0.17%	–
ONTY	Buy	ONCOTHYREON INC	$1,624,000	+84.5%	543,000	+8.6%	0.17%	+61.3%
BDSI	New	BIODELIVERY SCIENCES INTL IN	$1,604,000	–	190,000	+100.0%	0.17%	–
CSBR	Sell	CHAMPIONS ONCOLOGY	$1,609,000	-17.5%	1,625,299	-0.0%	0.17%	-27.8%
ANTH	Buy	ANTHERA PHARMACEUTICALS INC	$1,603,000	+21.0%	478,456	+10.9%	0.17%	+5.7%
ICAD	New	ICAD INC	$1,603,000	–	175,000	+100.0%	0.17%	–
ELOS	New	SYNERON MEDICAL LTDord	$1,587,000	–	127,500	+100.0%	0.17%	–
ENZ	New	ENZO BIOCHEM INC	$1,581,000	–	380,000	+100.0%	0.17%	–
RCPT	New	RECEPTOS INC	$1,468,000	–	35,000	+100.0%	0.15%	–
EXEL	New	EXELIXIS INCcall	$1,416,000	–	400,000	+100.0%	0.15%	–
NLNK	New	NEWLINK GENETICS CORPcall	$1,420,000	–	50,000	+100.0%	0.15%	–
ANIP	New	ANI PHARMACEUTICALS INC	$1,411,000	–	45,000	+100.0%	0.15%	–
DRRX	New	DURECT CORP	$1,206,000	–	907,064	+100.0%	0.13%	–
EPZM	New	EPIZYME INC	$1,198,000	–	52,602	+100.0%	0.13%	–
AKAOQ	New	ACHAOGEN INC	$928,000	–	60,000	+100.0%	0.10%	–
GLMD	New	GALMED PHARMACEUTICALS LTD	$860,000	–	75,000	+100.0%	0.09%	–
TBIO	New	TRANSGENOMIC INC	$842,000	–	183,957	+100.0%	0.09%	–
AGEN	New	AGENUS INC	$634,000	–	200,000	+100.0%	0.07%	–
VVUS		VIVUS INCput	$594,000	-34.6%	100,000	0.0%	0.06%	-43.1%
RGEN	Sell	REPLIGEN CORPput	$579,000	-74.3%	45,000	-72.7%	0.06%	-77.4%
BLUE		BLUEBIRD BIO INC	$455,000	+8.3%	20,000	0.0%	0.05%	-4.0%
MDGN		MEDGENICS INC	$428,000	+16.6%	61,263	0.0%	0.04%	+2.3%
BLRX	New	BIOLINERX LTDsponsored adr	$399,000	–	179,041	+100.0%	0.04%	–
ILMN	Buy	ILLUMINA INC	$372,000	+68.3%	2,500	+25.0%	0.04%	+44.4%
STEM		STEMCELLS INC	$364,000	+9.0%	271,600	0.0%	0.04%	-5.0%
T107PS	New	WRIGHT MED GROUP INC	$311,000	–	10,000	+100.0%	0.03%	–
INSYQ	Buy	INSYS THERAPEUTICS INC NEW	$255,000	+15.4%	6,153	+7.5%	0.03%	0.0%
XNPT		XENOPORT INC	$258,000	-10.4%	50,000	0.0%	0.03%	-22.9%
LCI		LANNET INC	$241,000	+8.1%	6,744	0.0%	0.02%	-7.4%
SCAI	Sell	SURGICAL CARE AFFILIATES INC	$230,000	-67.0%	7,472	-62.6%	0.02%	-71.4%
PTIE		PAIN THERAPEUTICS	$194,000	+12.8%	35,506	0.0%	0.02%	-4.8%
RIGL	New	RIGEL PHARMACEUTICALS INC	$194,000	–	50,000	+100.0%	0.02%	–
B108PS	New	ACTAVIS PLC	$195,000	–	945	+100.0%	0.02%	–
CSLT	New	CASTLIGHT HEALTH INC	$180,000	–	8,500	+100.0%	0.02%	–
HNT	Sell	HEALTH NET INC	$179,000	-97.8%	5,275	-98.1%	0.02%	-98.0%
CNC		CENTENE CORP DEL	$162,000	+5.2%	2,610	0.0%	0.02%	-5.6%
IPXL		IMPAX LABORATORIES INC	$158,000	+5.3%	5,962	0.0%	0.02%	-5.6%
VCRA	New	VOCERA COMMUNICATIONS INC	$163,000	–	10,000	+100.0%	0.02%	–
DVA		DAVITA HEALTHCARE PARTNERS I	$164,000	+8.6%	2,382	0.0%	0.02%	-5.6%
MDSO	Sell	MEDIDATA SOLUTIONS INC	$152,000	-30.9%	2,802	-23.1%	0.02%	-38.5%
HZNP	New	HORIZON PHARMA INC	$138,000	–	9,120	+100.0%	0.02%	–
HUM	New	HUMANA INC	$141,000	–	1,250	+100.0%	0.02%	–
PCRX	New	PACIRA PHARMACEUTICALS	$139,000	–	2,000	+100.0%	0.02%	–
FLDM	Buy	FLUIDIGM CORP DEL	$135,000	+73.1%	3,070	+51.2%	0.01%	+55.6%
ABMD	New	ABIOMED INC	$130,000	–	5,000	+100.0%	0.01%	–
ALR	Sell	ALERE INC	$127,000	-14.8%	3,700	-10.3%	0.01%	-27.8%
CI	Sell	CIGNA CORPORATION	$106,000	-99.0%	1,269	-99.0%	0.01%	-99.2%
OCR	Sell	OMNICARE INC	$103,000	-31.3%	1,732	-30.5%	0.01%	-38.9%
RAD		RITE AID CORP	$94,000	+23.7%	14,924	0.0%	0.01%	+11.1%
PBYI		PUMA BIOTECHNOLOGY	$76,000	0.0%	735	0.0%	0.01%	-11.1%
ENDP	New	ENDO INTL PLC	$78,000	–	1,138	+100.0%	0.01%	–
TXMD	New	THERAPEUTICSMD INC	$44,000	–	7,000	+100.0%	0.01%	–
CBMXW		COMBIMATRIX CORPORATIONw exp 5-1-2014	$9,000	+200.0%	5,000	0.0%	0.00%	–
STML		STEMLINE THERAPEUTICS INC	$1,000	0.0%	38	0.0%	0.00%	–
IMMU	Exit	IMMUNOMEDICS INC	$0	–	-2,853	-100.0%	-0.00%	–
AXGN	Exit	AXOGEN INC	$0	–	-4,500	-100.0%	-0.00%	–
GERN	Exit	GERON CORP	$0	–	-4,684	-100.0%	-0.00%	–
ENDP	Exit	ENDO HEALTH SOLUTIONS INC	$0	–	-1,138	-100.0%	-0.01%	–
AFFX	Exit	AFFYMETRIX INC	$0	–	-8,538	-100.0%	-0.01%	–
	Exit	ASTRAZENECA PLCsponsored adr	$0	–	-2,558	-100.0%	-0.02%	–
ESRX	Exit	EXPRESS SCRIPTS HLDG CO	$0	–	-2,080	-100.0%	-0.02%	–
	Exit	ANALOGIC CORP	$0	–	-1,644	-100.0%	-0.02%	–
HRC	Exit	HILL ROM HLDGS INC	$0	–	-3,687	-100.0%	-0.02%	–
TRNX	Exit	TORNIER N V	$0	–	-10,000	-100.0%	-0.02%	–
MYGN	Exit	MYRIAD GENETICS INCput	$0	–	-10,000	-100.0%	-0.02%	–
NAVB	Exit	NAVIDEA BIOPHARMACEUTICALS Iput	$0	–	-100,000	-100.0%	-0.02%	–
CUTR	Exit	CUTERA INC	$0	–	-22,400	-100.0%	-0.03%	–
ATHN	Exit	ATHENAHEALTH INCcall	$0	–	-2,500	-100.0%	-0.04%	–
NCT	Exit	NEWCASTLE INVT CORP	$0	–	-70,000	-100.0%	-0.05%	–
HOLX	Exit	HOLOGIC INCcall	$0	–	-25,000	-100.0%	-0.07%	–
NSPH	Exit	NANOSPHERE INC	$0	–	-295,000	-100.0%	-0.08%	–
	Exit	OREXIGEN THERAPEUTICS INCnote 2.750%12/0	$0	–	-750,000	-100.0%	-0.09%	–
UTHR	Exit	UNITED THERAPEUTICS CORP DEL	$0	–	-7,000	-100.0%	-0.10%	–
MDXG	Exit	MIMEDX GROUP INC	$0	–	-100,000	-100.0%	-0.10%	–
CRIS	Exit	CURIS INC	$0	–	-350,000	-100.0%	-0.12%	–
TBIO	Exit	TRANSGENOMIC INC	$0	–	-2,207,500	-100.0%	-0.12%	–
DXCM	Exit	DEXCOM INC	$0	–	-30,000	-100.0%	-0.13%	–
RPRX	Exit	REPROS THERAPEUTICS INC	$0	–	-71,879	-100.0%	-0.16%	–
SNTS	Exit	SANTARUS INC	$0	–	-45,400	-100.0%	-0.17%	–
BCRX	Exit	BIOCRYST PHARMACEUTICALS	$0	–	-197,500	-100.0%	-0.18%	–
NBS	Exit	NEOSTEM INC	$0	–	-229,593	-100.0%	-0.19%	–
ZBH	Exit	ZIMMER HLDGS INC	$0	–	-20,000	-100.0%	-0.22%	–
AUXL	Exit	AUXILIUM PHARMACEUTICALS INC	$0	–	-100,000	-100.0%	-0.25%	–
ECYT	Exit	ENDOCYTE INCput	$0	–	-200,000	-100.0%	-0.26%	–
ECYT	Exit	ENDOCYTE INCcall	$0	–	-200,000	-100.0%	-0.26%	–
ZGNX	Exit	ZOGENIX INC	$0	–	-650,000	-100.0%	-0.27%	–
INFI	Exit	INFINITY PHARMACEUTICALS INC	$0	–	-350,000	-100.0%	-0.58%	–
CVS	Exit	CVS CAREMARK CORPORATION	$0	–	-89,330	-100.0%	-0.77%	–
GENTY	Exit	GENTIUM S P Asponsored adr	$0	–	-120,000	-100.0%	-0.82%	–
CTIC	Exit	CELL THERAPEUTICS INC	$0	–	-3,715,000	-100.0%	-0.86%	–
HTWR	Exit	HEARTWARE INTL INC	$0	–	-84,900	-100.0%	-0.96%	–
	Exit	ANACOR PHARMACEUTICALS INC	$0	–	-487,542	-100.0%	-0.98%	–
BIIB	Exit	BIOGEN IDEC INC	$0	–	-40,000	-100.0%	-1.34%	–
SRPT	Exit	Sarepta Therapeutics Incput	$0	–	-650,000	-100.0%	-1.59%	–
MNKD	Exit	MANNKIND CORP	$0	–	-3,795,000	-100.0%	-2.38%	–
AEGR	Exit	AEGERION PHARMACEUTICALS INC	$0	–	-447,785	-100.0%	-3.82%	–

Original filings

The following EDGAR filing(s) were analyzed to create this report:

View 13F-HR filed 2014-05-15

Signatures

The EDGAR filing(s) were signed by:

Joseph Edelman — Managing Member

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings

Name	Quarters owned	Latest quarter owned	Max weighting
NEUROCRINE BIOSCIENCES SHARES	42	Q3 2023	15.7%
AMICUS THERAPEUTICS SHARES	39	Q3 2023	14.0%
ALDEYRA THERAPEUTICS SHARES	35	Q3 2023	3.3%
QUOTIENT TECHNOLOGY INC	34	Q3 2022	2.7%
GLOBAL BLOOD THERAPEUTICS SHARES	29	Q3 2022	9.3%
ADMA BIOLOGICS SHARES	29	Q3 2023	1.4%
RETROPHIN SHARES	28	Q3 2020	5.5%
DBV TECHNOLOGIES SA-SPON ADR	28	Q3 2021	1.8%
VBI VACCINES SHARES	27	Q1 2023	2.8%
IOVANCE BIOTHERAPEUTICS INC	26	Q3 2023	9.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)

Perceptive Advisors Q1 2014 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
	Filed	Shares	Percentage
CHEMBIO DIAGNOSTICS, INC.^{Sold out}	May 04, 2023	0	0.0%
VBI Vaccines Inc/BC	April 07, 2023	43,509,553	16.7%
Landos Biopharma, Inc.	March 30, 2023	14,869,915	47.7%
REATA PHARMACEUTICALS INC	March 07, 2023	2,083,799	6.5%
AGILE THERAPEUTICS INC^{Sold out}	February 14, 2023	0	0.0%
ALBIREO PHARMA, INC.	February 14, 2023	1,757,160	8.5%
BELLUS Health Inc.	February 14, 2023	8,891,027	7.1%
CinCor Pharma, Inc.	February 14, 2023	2,576,325	5.9%
Coherus BioSciences, Inc.^{Sold out}	February 14, 2023	0	0.0%
CONCERT PHARMACEUTICALS, INC.	February 14, 2023	1,800,000	3.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings

Type	Filed
SC 13D/A	2024-04-17
SC 13D/A	2024-04-17
4	2024-04-15
SC 13G/A	2024-04-15
SC 13G	2024-04-15
SC 13D/A	2024-04-10
4	2024-04-08
4	2024-04-03
SC 13D/A	2024-04-03
SC 13D	2024-03-20

View Perceptive Advisors's complete filings history.

All filings

View complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

The reported total value is incorrect (951681000.0 != 951682000.0)

Export Perceptive Advisors's holdings